Cellink

Cellink

HQ Country
United States
Profile
CELLINK is the first company in the world to commercialize a universal bioink for 3D Bioprinting of human tissues and organs. Along with producing bioinks, CELLINK also manufactures state of the art cost-effective 3D Bioprinters. As a global leader in 3D Bioprinting technology, CELLINK is working closely with hundreds of leading research institutions such as the FDA, Harvard and MIT.
Filtered by:
Cellink
Company
Topic
Show
 
2020
9 Jun 2020

3D Bioprinted Organs in the Discovery and Development of Medicines

3D bioprinting provides scientists with the unique ability to create artificial tissue that closely resembles native tissue in form and function. A method of tissue engineering, 3D bioprinting is the precise deposition of cells, typically layer-by-layer, to realize a final 3D construct. Over the years, 3D bioprinting has seen increased adoption as a research tool and as a method for tissue engineering in regenerative medicine.
2019
5 Mar 2019

IDTechEx showcases why Boston is at heart of 3D printing revolution

3D printing is rapidly reaching industrial commercialisation in numerous sectors; IDTechEx forecast that the total market will be worth $22bn by 2028. A new 3D Printing commercial insight forum is being hosted at the Autodesk facilities in Boston, USA, May 8-9 2019. This event provides expert led sessions giving technical analysis, commercial understanding and market outlooks across key topic areas. Each session will be conducted by an IDTechEx analyst and include a high-profile industrial speaker to give their key findings and opinions.
30 Jan 2019

Toyota highlight the significance of 3D printing in lightweight design

3D printing is rapidly reaching industrial commercialisation in numerous sectors; IDTechEx forecast that the total market will be worth $22bn by 2028. One of the key features is the design freedom this technology enables where, alongside other functional advantages, a major opportunity is in lightweighting.
2018
19 Dec 2018

The coming of age of 3D bioprinting?

Though activities in 3D bioprinting have been growing in leaps and bounds since 2015, the activity we have seen in 2018 has been truly remarkable for this fledgling field. Finally, governments, academic institutions and companies alike are beginning to understand the value that 3D bioprinting can bring and are working hard together to bring disruptive change through building tissues from scratch.
24 Oct 2018

Demonstration of CellInk's new BioX bioprinter

Dr Nadia Tsao, an IDTechEx Analyst met with a representative of CellInk to discuss their developments in the bioprinting sector, specifically their BioX bioprinter.
15 Oct 2018

Cellink

IDTechEx analyst Nadia Tsao spoke with Cellink CEO Erick Gatenholm and Cellink Head of Global Sales Johan Berthag at TERMIS WC 2018.
12 Oct 2018

3D Printing in the Medical and Dental Industry 2019 - 2029

IDTechEx Report: Dr Bryony Core and Dr Nadia Tsao
10 Aug 2018

Crocodile cartilage, human stem cells for 3D printed joint cartilage

A microbiologist in central Queensland is using 3D printing, human stem cells, and crocodile cartilage to find a new way to treat arthritis and joint injuries.
17 May 2018

Cellink

Update from the IDTechEx Show! Europe 2018
12 Apr 2018

3D Bioprinting Of Human Soft Tissues

Cellink, Sweden
13 Mar 2018

3D Bioprinting 2018 - 2028: Technologies, Markets, Forecasts

IDTechEx Report: Dr Nadia Tsao
2017
10 Nov 2017

Tissue Engineering 2018-2028: Technologies, Markets, Forecasts

IDTechEx Report: Dr Nadia Tsao
9 May 2017

3D bioprinting - from science fiction to reality?

After over 15 years of research and development in academia and industry, several main applications of 3D bioprinting technology are ready to be realised.
20 Apr 2017

Cellink

IDTechEx analyst Nadia Tsao interviewed Cellink CEO Erik Gatenholm on April 20, 2017. The company focuses on developing a range of bioinks for 3D bioprinting, and also manufactures several 3D bioprinters.
Included are: